Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Common Stock Issued
Cash raised by issuing new shares.
Maze Therapeutics, Inc.NASDAQ: MAZE
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued declines year over year
Q1 FY2026 common stock issued of $3.84M fell 97.0% year over year, ahead of the -160.7% change in trailing-twelve-month common stock issued. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +442.5% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -97.0% holds above the trailing-twelve-month pace of -160.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 275.84M USD
- Year-over-year change
- +303.4%
- 3-year CAGR
- +442.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 275.84M | +303.4% |
| FY2024 | 2024-12-31 | 68.37M | +32613.9% |
| FY2023 | 2023-12-31 | 209K | -87.9% |
| FY2022 | 2022-12-31 | 1.73M | — |
Common Stock Issued vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -160.7% is the lowest of 7, against a peer median of +87.2%.
- Common stock issued amounts to 601.6% of revenue for MAZE, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €237.74M EUR | +314.6% | +199.8% | 5303.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $143.89M USD | +420.9% | +640.5% | 1394.8% |
| LTM Mar 2026 | $120.32M USD | -160.7% | +442.5% | 601.6% | |
| LTM Jun 2026 | $102.13M USD | +121.2% | +25.6% | 10.1% | |
| LTM Mar 2026 | $44.53M USD | — | — | — | |
| LTM Sep 2026 | $27.2M USD | -81.2% | +24.3% | 4.2% | |
| LTM Mar 2026 | $9.8M USD | +53.2% | -56.6% | 2.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.02M USD | -99.7% | +174.2% | 1.1% |
| Peer median (excluding MAZE) | — | +87.2% | +99.9% | 7.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.